Suchánková A, Krchnák V, Vágner J, Hamsíková E, Krcmár M, Ritterová L, Vonka V
Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czechoslovakia.
J Gen Virol. 1992 Feb;73 ( Pt 2):429-32. doi: 10.1099/0022-1317-73-2-429.
Eight overlapping icosapeptides covering the entire sequence of the E4 protein of human papillomavirus type 16 (HPV-16), were prepared and tested for their reactivity with human sera in IgG-specific ELISA. The strongest reactivity of sera from HPV-16 DNA-positive invasive cervical carcinoma (INCA) patients was detected with the peptide denoted 16/E4-6, covering amino acids 51 to 70. Subsequently nearly 200 sera were tested for the presence of the 16/E4-6-specific antibody. Reactivity was more frequent in cervical intraepithelial neoplasia patients and INCA patients than in matched control subjects. Sera from INCA patients were also tested for antibody reactive with peptide 16/E7-2 covering the major type-specific reactive region of the HPV-16 E7 protein. Only four of 13 sera possessing the 16/E4-6-specific antibody were reactive with the 16/E7-2 peptide.
制备了覆盖人乳头瘤病毒16型(HPV - 16)E4蛋白完整序列的8种重叠二十肽,并在IgG特异性酶联免疫吸附测定(ELISA)中检测它们与人血清的反应性。在HPV - 16 DNA阳性浸润性宫颈癌(INCA)患者血清中,与标记为16/E4 - 6(覆盖氨基酸51至70)的肽反应最强。随后检测了近200份血清中16/E4 - 6特异性抗体的存在情况。宫颈上皮内瘤变患者和INCA患者血清的反应性比匹配的对照受试者更常见。还检测了INCA患者血清与覆盖HPV - 16 E7蛋白主要型特异性反应区域的肽16/E7 - 2的抗体反应性。在拥有16/E4 - 6特异性抗体的13份血清中,只有4份与16/E7 - 2肽反应。